International Journal of Psychiatry in Clinical Practice
June 1, 2026
Damian Swieczkowski, Aleksander Kwaśny, Michal Pruc et al.
To explore sex, racial and ethnic disparities in esketamine clinical trials for mental health disorders registered on ClinicalTrials.gov. We conducted a registry-based cross-sectional analysis of interventional esketamine trials with results posted on ClinicalTrials.gov (cut-off date: 10 February 2025). Using predefined eligibility criteria, two investigators independently extracted and...
International Journal of Psychiatry in Clinical Practice
April 29, 2026
David Eckert, Siegfried Kasper
The treatment of treatment-resistant depression (TRD) remains a clinical challenge. Pharmacologically, several augmentation options exist. The aim of this study was to present a mechanistically informed and clinically oriented decision-making framework for the established strategies of lithium, quetiapine, and esketamine. We conducted a narrative, non-systematic review, performing a targeted...
International Journal of Psychiatry in Clinical Practice
March 11, 2026
Michele Prato, Matteo Carminati, Filippo Frizzi et al.
1 citation
Background: Treatment-Resistant Depression (TRD) often persists despite adequate pharmacotherapy. Intranasal Esketamine and accelerated repetitive Transcranial Magnetic Stimulation (aTMS) are rapid-acting options, but head-to-head comparisons remain limited. Methods: We conducted a retrospective study on TRD patients receiving either aTMS (n = 18) or Intranasal Esketamine (n = 22). Depression...
International Journal of Psychiatry in Clinical Practice
March 2026
Guoguang Song, Ugwah-Oguejiofor Chinenye Jane
Electroconvulsive therapy (ECT) has long been considered the main method of treatment for patients with resistant major depressive disorder (MDD). Recent studies have shown that ketamine infusion can also effectively improve treatment-resistant MDD. Thus, we conducted this meta-analysis to compare the efficacy of ketamine with ECT for treating treatment-resistant depression. We systematically...
International Journal of Psychiatry in Clinical Practice
February 7, 2026
Daniel Pustay, Vishal Patel, Krista Ulisse et al.
Treatment-resistant depression (TRD) remains a complex challenge, often requiring interventions beyond standard medications. This review explores factors that may predict positive response to electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS) and ketamine-based treatments to help guide clinical decision-making. A systematic review was conducted following PRISMA...
International Journal of Psychiatry in Clinical Practice
July 10, 2025
Stefan Jerotić, Milica Nestorovic, Janko Nešić et al.
3 citations
These two cases highlight the utility of a focused, structured clinical phenomenological interview in measuring treatment effectiveness in subjective experience. Two male patients, aged 35 and 27, of Serbian ethnicity with treatment-resistant depression were treated with nasal esketamine, with clinical progress monitored using both the Montgomery-Åsberg Depression Rating Scale (MADRS) and the...
International Journal of Psychiatry in Clinical Practice
June 1, 2024
Ludovic Samalin, Lila Mekaoui, Pierre De Maricourt et al.
3 citations
ESKALE is a French, multicentre, observational study of adults with treatment-resistant depression (TRD) treated with esketamine. This interim analysis describes baseline demographic and clinical characteristic evolution in patients included and treated from early access program to post-marketing launch. Data were collected from medical records and included patient characteristics, disease...
International Journal of Psychiatry in Clinical Practice
2024
Marie Spies, Siegfried Kasper, Richard Frey et al.
Modern electroconvulsive therapy (ECT) and ketamine currently represent the most effective treatment options in depressed patients showing non-response to two or more trials of antidepressants. Recently, large sample head-to-head comparisons of intravenous ketamine versus ECT for treatment-resistant depression (TRD) have fuelled the debate on which therapy might be more effective. However, the...
International Journal of Psychiatry in Clinical Practice
November 2022
Ludovic Samalin, Maud Rothärmel, Lila Mekaoui et al.
To present the first real-world data of patients with treatment-resistant depression (TRD) treated with esketamine through a French cohort Temporary Authorisation for Use (ATUc) programme. In 2019, the French Health Authorities exceptionally granted the first ATUc in psychiatry for TRD patients. Clinical characteristics, safety and efficacy data were reported by physicians. The ATUc ended ∼6...
International Journal of Psychiatry in Clinical Practice
April 15, 2021
Raghav Shah, Abhishek Ghosh, A. Avasthi et al.
Abstract Objective Cannabis-induced psychosis (CIP) has received little research attention. We compared neurocognitive functions in CIP, Schizophrenia with cannabis use (SZC) and healthy control group (CG). Methods Twenty age, education, and handedness-matched participants were recruited in each of the three groups. CIP and SZC were diagnosed with Psychiatric research interviews for substance...
International Journal of Psychiatry in Clinical Practice
November 2018
Angela Potes, Gabriel Souza, Katerina Nikolitch et al.
This systematic review summarises the current state of research on mindfulness in SPMI, given the pressing need to provide alternative, scalable and cost-effective treatment modalities for patients with severe and persistent mental illness (SPMI). Articles included mindfulness-based interventions for SPMI. Excluded articles included qualitative studies, acceptance and compassion therapies, case...
International Journal of Psychiatry in Clinical Practice
June 2017
Janusz Rybakowski, Agnieszka Permoda‐osip, Alicja Bartkowska-Sniatkowska
To study the clinical effect of a single ketamine infusion, 0.5 mg/kg body weight, in bipolar depressive patients receiving mood-stabilising drugs, not improving on antidepressants. Previously, in such patients, we had found a correlation between clinical efficacy, serum brain-derived neurotrophic factor and vitamin B12 levels and a rapid improvement in neurocognitive performance. The study...
International Journal of Psychiatry in Clinical Practice
March 2017
Christoph Kraus, Ulrich Rabl, Thomas Vanicek et al.
Clinical trials demonstrated that ketamine exhibits rapid antidepressant efficacy when administered in subanaesthetic dosages. We reviewed currently available literature investigating efficacy, response rates and safety profile. Twelve studies investigating unipolar, seven on bipolar depression were included after search in medline, scopus and web of science. Randomized, placebo-controlled or...
International Journal of Psychiatry in Clinical Practice
September 1, 2016
Katerina Nikolitch, Vincent Laliberté, Ching Yu et al.
Mindfulness-oriented therapies have a positive impact on patients' overall well-being and alleviate many psychiatric conditions. However, little is known about their use in people with severe mental illness. We aimed to identify which clinical and sociodemographic factors are associated with suitability/tolerability of a brief group mindfulness-oriented therapy. This retrospective study...